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Background: Ischemic stroke causes a high rate of deaths and permanent neurological damage in survivors. Ischemic
stroke triggers the release of damage-associated molecular patterns (DAMPs) such as high-mobility group box 1
(HMGB1), which activate toll-like receptors (TLRs) and receptor for advanced glycation endproducts (RAGE) in the
affected area, leading to an exaggerated inflammatory response and cell death. Both TLRs and RAGE are transmembrane
pattern recognition receptors (PRRs) that have been shown to contribute to ischemic stroke-induced brain injury.
Intravenous immunoglobulin (IVIg) preparations obtained by fractionating human blood plasma are increasingly
being used as an effective therapeutic agent in the treatment of several inflammatory diseases. Its use as a potential
therapeutic agent for treatment of stroke has been proposed, but little is known about the direct neuroprotective
mechanisms of IVIg. We therefore investigate whether IVIg exerts its beneficial effects on the outcome of
neuronal injury by modulating HMGB1-induced TLR and RAGE expressions and activations.
Methods: Primary cortical neurons were subjected to glucose deprivation or oxygen and glucose deprivation
conditions and treated with IVIg and recombinant HMGB1. C57/BL6J mice were subjected to middle cerebral
artery occlusion, followed by reperfusion, and IVIg was administered intravenously 3 h after the start of reperfusion.
Expression of TLRs, RAGE and downstream signalling proteins in neurons and brain tissues were evaluated by
immunoblot.
Results: Treatment of cultured neurons with IVIg reduced simulated ischemia-induced TLR2, TLR4, TLR8 and RAGE
expressions, pro-apoptotic caspase-3 cleavage and phosphorylation of the cell death-associated kinases such as
c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK) as well as the p65 subunit of nuclear
factor kappa B (NF-κB). These results were recapitulated in an in vivo model of stroke. IVIg treatment also upregulated
the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in cortical neurons under ischemic conditions. Finally, IVIg
protected neurons against HMGB1-induced neuronal cell death by modulating TLR and RAGE expressions and
signalling pathways.
Conclusions: Taken together, these results provide a rationale for the potential use of IVIg to target inappropriately
activated components of the innate immune system following ischemic stroke.
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Figure 1 IVIg treatment inhibits the increased expressions of TLRs in cultured cortical neurons subjected to simulated ischemia. (A-D) Representative
2immunoblots and quantification illustrating increases in the levels of TLR2, TLR4 and TLR8 proteins in primary cortical neurons at indicated
times during GD. Administration of IVIg (5 and 10 mg/ml) significantly prevents GD-induced increased expression of TLR2, TLR4 and TLR8. Data
are represented as mean ± SEM. n = 5 cultures. *P < 0.05 in comparison with normal; **P < 0.01 in comparison with normal; ***P < 0.001 in comparison
with normal; +++P < 0.001 in comparison with vehicle-treated group. (E-H) Representative immunoblots and quantification illustrating increases in the
levels of TLR2, TLR4 and TLR8 proteins in primary cortical neurons at indicated times during OGD. Administration of IVIg (5 and 10 mg/ml) significantly
prevents OGD-induced increased expression of TLR2, TLR4 and TLR8. Data are represented as mean ± SEM. n = 5 cultures. **P < 0.01 in comparison with
normal; ***P < 0.001 in comparison with normal; +P < 0.05 in comparison with vehicle-treated group; ++P < 0.01 in comparison with vehicle-treated
group; +++P < 0.001 in comparison with vehicle-treated group.
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Toll-like receptors (TLRs) are expressed in a variety of
mammalian immune-related cell types and initiate signals
in response to diverse pathogen-associated molecular pat-
terns (PAMPs) [1]. The signalling pathways activated by
the TLRs are broadly classified into MyD88-dependent
and -independent pathways [2]. Upon receptor activation
and interaction with MyD88, one or more of the toll/
interleukin-1 receptor (TIR)-containing adapter proteins
are recruited and MyD88 binds with the TIR domain of
the receptor and phosphorylates interleukin-1 receptor-
associated kinase 4 (IRAK4), which, in turn, phosphorylates
IRAK1. After being phosphorylated, IRAK1 dissociates
from MyD88 and interacts with TRAF6. TRAF6 forms
a complex that activates downstream signalling of TLRs
[1]. Major downstream signalling pathways activated by
TLR engagement include the nuclear factor kappa B (NF-
κB) and mitogen-activated protein kinases (MAPKs) such
as c-Jun N-terminal kinase (JNK) and p38 MAPK cascades.
The MyD88-independent pathway signals through the
adaptor TIR-domain-containing adaptor protein indu-
cing interferon (IFN)-β-mediated transcription factor
(TRIF) [1]. TRIF interacts with TRAF3 leading to the
recruitment and activation of tumour necrosis factor
(TNF) receptor-associated factor-family member-associated
NF-κB activator-binding kinase 1 (TBK1) and inhibitor of
nuclear factor kappa-B kinase subunit epsilon (IKKε). This
culminates in interferon regulatory factor 3 (IRF3) phos-
phorylation that facilitates IRF3 dimerization and trans-
location into the nucleus and transcriptional regulation.
In relation to cerebral ischemia, it has been shown that
disruption of downstream MyD88-independent (TRIF)
TLR pathway does not confer protection in in vitro and
in vivo models of cerebral ischemia [3]. A variety of en-
dogenous ligands, such as high-mobility group box 1
(HMGB1), also bind to TLR and activate several intra-
cellular inflammatory pathways, including the NF-κB, JNK
and p38 MAPK pathways [4,5]. The presence of several
TLRs has been reported in the brain, both in glial and
neuronal cells [6-9], and recent studies have reported the
pathological roles of TLR2, TLR4 and TLR8 in ischemic
stroke-induced brain injury [7,9-12]. Neurons were found
to express TLR2, TLR4 and TLR8 under both physio-
logical and pathological conditions, and cortical neuronalcultures from both TLR2 and TLR4 deficient mice were
protected against cell death induced by energy deprivation
(an in vitro model of ischemic stroke) when compared
with wild type [7]. Furthermore, we have recently provided
evidence that neuronal TLR8 signalling plays a detrimental
role by triggering post-stroke inflammation and neuronal
cell death [9].
Intravenous immunoglobulin (IVIg) is an FDA-approved
therapeutic modality used for various autoimmune and in-
flammatory diseases [13]. Recently, we demonstrated that
IVIg treatment significantly reduced brain infarct volume
and mortality in an experimental mouse model of ischemic
stroke [14,15]. IVIg has also been shown to inhibit comple-
ment activation, modulate cytokine production, reduce
endothelial dysfunction and death, reduce activation and
infiltration of leukocytes, as well as inhibit neuronal apop-
tosis by decreasing the cleavage of caspase-3 in primary
cortical neurons subjected to ischemic insults [14,15]. It
was recently shown that IVIg may modulate TLR9 expres-
sion and activation in pathological conditions such as
systemic lupus erythematosus (SLE), suggesting a new
additional mechanism of IVIg [16]. IVIg has also been
shown to modulate the maturation of TLR-primed per-
ipheral blood monocytes [17]. In addition, IVIg suppresses
TLR4-induced cytokine production induced by lipopoly-
saccharide (LPS) by inhibiting the NF-κB, JNK and p38
MAPK pathways in human monocytic cells [18]. IVIg also
attenuates multiple cell death pathways by decreasing the
phosphorylation of the p65 subunit of NF-κB, JNK, p38
MAPK and c-Jun, in simulated ischemic condition [15].
However, relatively little is known about the role of IVIg
in modulating the expression and activation of TLRs and
endogenous ligand-mediated TLR activation following is-
chemic stroke. Here, we provide the first evidence that
IVIg protects neurons by decreasing the expression and
activation of TLRs and by suppressing HMGB1-mediated
TLR activation. Our findings further support IVIg as a po-
tential therapeutic modality for targeting ischemic stroke-
induced neuronal cell death and brain injury.
Methods
Primary cortical neuronal cultures
Dissociated neuron-enriched cell cultures of mouse cere-
bral cortex were established from day 16 C57BL/6 J mouse
Figure 2 (See legend on next page.)
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Figure 2 IVIg treatment prevents the increased expressions of TLR adaptor and signalling proteins. IVIg treatment prevents the increased expressions
of TLR adaptor and signalling proteins in cultured cortical neurons subjected to simulated ischemia. (A-C) Representative immunoblots and
quantification illustrating increases in the levels of MyD88 and TRAF6 proteins in primary cortical neurons at indicated times during GD.
Administration of 10 mg/ml of IVIg significantly prevents the increase in MyD88 and TRAF6 protein expression caused by 6, 12 and 24 h of
GD; the effect of 5 mg/ml IVIg was significant at 12 and 24, but not 6 h of GD. Data are represented as mean ± SEM. n = 5 cultures. **P < 0.01
in comparison with normal; ***P < 0.001 in comparison with normal; +++P < 0.001 in comparison with vehicle-treated group; ns, not significant.
(D-F) Representative immunoblots and quantification illustrating increases in the levels of MyD88 and TRAF6 proteins in primary cortical neurons at
indicated times during OGD. Administration of IVIg (5 and 10 mg/ml) significantly prevents an increased expression level of MyD88 and TRAF6 proteins
following 6 and 12 h of OGD. Data are represented as mean ± SEM. n = 5 cultures. *P < 0.05 in comparison with normal; ***P < 0.001 in comparison with
normal; ++P < 0.01 in comparison with vehicle-treated group; +++P < 0.001 in comparison with vehicle-treated group.
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performed in 7- to 9-day-old cultures. Approximately
95% of the cells in such cultures were neurons, and the
remaining cells were astrocytes.
Glucose deprivation and combined oxygen-glucose
deprivation
For glucose deprivation (GD) studies, glucose-free Locke’s
buffer containing: 154 mM NaCl, 5.6 mM KCl, 2.3 mM
CaCl2, 1 mM MgCl2, 3.6 mM NaHCO3, 5 mM HEPES,
pH 7.2, supplemented with gentamicin (5 mg/L) was used.
The cultured neurons were incubated in glucose-free
Locke’s buffer for up to 24 h. For combined oxygen and
glucose deprivation (OGD) studies, neurons were incubated
in glucose-free Locke’s buffer in an oxygen-free chamber
for 4.5, 6 or 12 h. To observe the effect of IVIg, IVIg
(KIOVIG, Baxter) was added at the reported concentra-
tions to the cultures during GD or OGD conditions.
The active ingredient in KIOVIG is a human plasma-
derived immunoglobulin, concentration of 100 mg/mL
(10% w/v), produced from large pools of human plasma
by a modified Cohn-Oncley cold ethanol fractionation,
yielding an intermediate immunoglobulin G, referred to
as precipitate G. Equal concentration of glycine (Sigma
Aldrich, St. Louis, MO, USA), an amino acid with no
known affinity for any cell receptors, was also included
in the experiments as vehicle control for IVIg. To ob-
serve the effect of HMGB1, mouse recombinant HMGB1
(Source: E. coli expressed amino acids Met1-Glu215 of
mouse HMGB-1 accession # NM_010439; purity: >98%;
endotoxin: less than 0.01 ng/μg cytokine) (34-8401,
eBioscience, San Diego, CA, USA) was added either alone
or simultaneously with IVIg to the OGD-treated neuronal
cultures.
Western blot analysis
Protein samples were subjected to sodium dodecyl sulphate-
polyacrylamide (7.5% or 10%) gel electrophoresis using a
Tris-glycine running buffer (Bio-Rad, Hercules, CA, USA).
Gels were then electro-blotted using a semi-dry transfer ap-
paratus (Bio-Rad) in transfer buffer containing 0.025 mol/L
Tris base, 0.15 mol/L glycine and 10% (v/v) methanol for
1.5 h at 350 mA onto nitrocellulose membranes (Bio-Rad).The membranes were then incubated in blocking buffer [5%
bovine serum albumin (BSA) or 5% non-fat milk in TBS-T
(20 mmol/L Tris-HCl, pH 7.5, 137 mmol/L NaCl, 0.2%
Tween-20)] for 1 h at room temperature. The membranes
were then incubated overnight at 4°C with primary anti-
bodies including those that selectively bind TLR2 (Abcam,
Cambridge, UK), TLR4 (Abcam), TLR8 (Abcam), RAGE
(Abcam), MyD88 (Abcam), TRAF6 (Abcam), p-JNK (Cell
Signaling, Danvers, MA, USA), p-p38 MAPK (Cell Sig-
naling), p-p65 (Cell Signaling), p-c-Jun (Cell Signaling),
Bcl-2 (Cell Signaling), cleaved caspase-3 (Cell Signaling),
HMGB1 (Cell Signaling) and β-actin (Sigma Aldrich).
After washing three times (10 min per wash) with TBS-
T, the membranes were incubated with horseradish
peroxidase-conjugated secondary antibodies for 1 h at
room temperature. The membranes were then washed
again with TBS-T and incubated with chemiluminescent
substrate for enhanced chemiluminescence (Thermo Fisher
Scientific, Waltham, MA, USA) for 5 min. The signals were
visualized by exposing the membranes onto X-ray films
(Fujifilm Corporation, Minato, Tokyo, Japan).
Middle cerebral artery occlusion and reperfusion
12- to 14-week-old C57BL/6 J male mice were used for
in vivo experiments. The focal cerebral ischemia/reperfusion
(I/R) model was similar to that described previously [20].
Briefly, the mice were anesthetized with isoflurane, a
midline incision was made in the neck, and the left ex-
ternal carotid and pterygopalatine arteries were isolated
and ligated with 6-0 silk thread. The internal carotid artery
(ICA) was occluded at the peripheral site of the bifur-
cation of the ICA and the pterygopalatine artery using
a small clip, and the common carotid artery (CCA) was
ligated with 6-0 silk thread. The external carotid artery
(ECA) was cut, and a 6-0 nylon monofilament with a
blunted tip (0.2 to 0.22 mm) with a coagulator was inserted
into the ECA. After the clip at the ICA was removed, the
nylon monofilament was advanced into the origin of the
middle cerebral artery (MCA) until light resistance was felt.
The nylon monofilament and the CCA ligature were re-
moved after 1 h of occlusion to initiate reperfusion. In the
sham-operated group, these arteries were visualized but
not disturbed. Mice were administered with 1 g/kg body
Figure 3 (See legend on next page.)
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Figure 3 IVIg treatment down regulates the expressions of the phosphorylated forms of TLR signalling cascade components. IVIg treatment
down regulates the expressions of the phosphorylated forms of TLR signalling cascade components in cultured cortical neurons subjected to
simulated ischemia. (A-E) Representative immunoblots and quantification illustrating increases in the levels of NF-κB-p-p65 and p-p38 MAPK in
primary cortical neurons at indicated times during GD. Administration of IVIg (5 and 10 mg/ml) significantly attenuated the expression level of
NF-κB-p-p65, p-JNK, p-p38 MAPK and p-c-Jun in GD 6-, 12- and 24-h-treated neurons. Data are represented as mean ± SEM. n = 5 cultures.
*P < 0.05 in comparison with normal; **P < 0.01 in comparison with normal; ***P < 0.001 in comparison with normal; +P < 0.05 in comparison
with vehicle-treated group; ++P < 0.01 in comparison with vehicle-treated group; +++P < 0.001 in comparison with vehicle-treated group. (F-J)
Representative immunoblots and quantification illustrating increases in the levels of NF-κB-p-p65 and p-p38 MAPK in primary cortical neurons
at indicated times during OGD. Administration of IVIg (5 and 10 mg/ml) significantly attenuated the expression level of NF-κB-p-p65, p-JNK
and p-p38 MAPK in OGD 6- and 12-h-treated neurons. Administration of 10 mg/ml IVIg significantly attenuated the expression level of p-c-Jun
in OGD 6- and 12-h-treated neurons, however the effect of 5 mg/ml IVIg was significant at 12 but not 6 h of OGD. Data are represented as
mean ± SEM. n = 5 cultures. *P < 0.05 in comparison with normal; ***P < 0.001 in comparison with normal; +P < 0.05 in comparison with vehicle-treated
group; ++P < 0.01 in comparison with vehicle-treated group; +++P < 0.001 in comparison with vehicle-treated group; ns, not significant.
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(approximately 250 μL) 3 h after the start of reperfusion
period. Cerebral blood flow was measured by placing the
animal’s head in a fixed frame after it had been anesthetized
and prepared for surgery. A craniotomy was performed to
access the left middle cerebral artery and was extended to
allow positioning of a 0.5-mm Doppler probe (Moor LAB,
Moor Instruments, Devon, UK) over the underlying parietal
cortex approximately 1 mm posterior to the bregma and
1 mm lateral to the midline. The animals were included in
the study if they underwent successful MCA occlusion, de-
fined by an 80% or greater drop in cerebral blood flow seen
with laser Doppler flowmetry. The animals were excluded if
insertion of the thread resulted in perforation of the vessel
wall determined by the presence of sub-arachnoid blood at
the time of sacrifice. University of Queensland Animal
Care and Use Committee approved all in vivo experimen-
tal procedures.
Statistical analysis
All numerical values are expressed as mean ± SEM. The
overall significance of the data was examined by one-way
analysis of variance (ANOVA) followed by Newman-Keuls
post hoc test to determine group differences. Statistical dif-
ference was considered as P < 0.05 throughout the study.
Statistical analyses were performed using GraphPad Prism
software.
Results
IVIg treatment reduces expression and activation of TLRs
in primary cortical neurons subjected to GD and OGD
conditions
We first evaluated the effect of IVIg on the protein expres-
sions of TLR2, TLR4 and TLR8 in a cell culture model of
ischemic neuronal injury in which primary mouse cortical
neurons were subjected to conditions mimicking ischemic
stroke, including glucose deprivation (GD) and combined
oxygen and glucose deprivation (OGD) (Figure 1). We
have previously shown that low concentrations (0.1 and
0.3 mg/ml) of IVIg significantly increased in vitro ischemicstress-induced neuronal cell death whereas high concen-
trations (5 and 10 mg/ml) of IVIg significantly decreased
GD-induced neuronal cell death [15]. Therefore, we used
5 and 10 mg/ml in this study to test the effect of IVIg
against TLR expression and activation. Immunoblot ana-
lyses showed that treatment with IVIg (5 and 10 mg/ml)
significantly prevented GD-induced increased expres-
sions of TLR2, TLR4 and TLR8 following 6, 12 and 24 h
(Figure 1A-D). Treatment with IVIg (5 and 10 mg/ml)
also significantly prevented 6 and 12 h OGD-induced in-
creased neuronal expressions of TLR2, TLR4 and TLR8
(Figure 1E-H). We next analysed the effect of IVIg on the
expression levels of myeloid differentiation primary re-
sponse gene (88) (MyD88) and TNF receptor-associated
factor 6 (TRAF6) following GD and OGD conditions.
Both of these proteins are involved in the downstream
signalling of TLR2, TLR4 and TLR8. Our immunoblot
analyses showed that GD- and OGD-induced upregu-
lation of MyD88 and TRAF6 levels at different time
points was significantly prevented by IVIg treatment
(Figure 2A-F).
IVIg modulates neuronal NF-κB and MAPK activities and
protects neurons against apoptotic cell death following
simulated ischemic condition
Because the activation of NF-κB, JNK and p38 MAPK
pathways are implicated in TLR2, TLR4 and TLR8 sig-
nalling and ischemia-induced neuronal cell death [10,21],
we next measured the protein levels of phosphorylated
p65 (a subunit of NF-κB), JNK, p38 MAPK and c-Jun
following GD and OGD in IVIg-treated neurons com-
pared with control neurons. Treatment with both 5 and
10 mg/ml of IVIg significantly attenuated the expres-
sion level of the phosphorylated forms of NF-κB p65
(Figure 3A,B), JNK, p38 MAPK and c-Jun following 6,
12 and 24 h of GD when compared to the vehicle-
treated group (Figure 3A,C-E). We also measured the
levels of these proteins under OGD conditions. Immuno-
blot analyses showed that IVIg treatments attenuated the
expression level of the phosphorylated forms of NF-κB
Figure 4 (See legend on next page.)
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Figure 4 IVIg protects cultured neurons against simulated ischemia. (A, B) Treatment with high concentrations of IVIg (5 and 10 mg/ml) significantly
prevents GD-induced increased expression of pro-apoptotic cleaved caspase-3 following 6, 12 and 24 h. Data are represented as mean ± SEM. n = 5
cultures. ***P < 0.001 in comparison with normal; +P < 0.05 in comparison with vehicle-treated group; ++P < 0.01 in comparison with vehicle-treated
group; +++P < 0.001 in comparison with vehicle-treated group. (A, C) Treatment with high concentrations of IVIg (5 and 10 mg/mL) significantly
increased the expression level of anti-apoptotic Bcl-2 following 6, 12 and 24 h of GD. Data are represented as mean ± SEM. n = 5 cultures.
+P < 0.05 in comparison with vehicle-treated group; +++P < 0.001 in comparison with vehicle-treated group; ns, not significant. (D, E) Treatment
with high concentrations of IVIg (5 and 10 mg/mL) significantly prevents OGD-induced increased expression of pro-apoptotic cleaved caspase-3
following 6 and 12 h. Data are represented as mean ± SEM. n = 5 cultures. **P < 0.01 in comparison with normal; ***P < 0.001 in comparison with
normal; +P < 0.05 in comparison with vehicle-treated group; ++P < 0.01 in comparison with vehicle-treated group; +++P < 0.001 in comparison with
vehicle-treated group. (D, F) Treatment with high concentrations of IVIg (5 and 10 mg/mL) significantly prevents a decreased level of anti-apoptotic
Bcl-2 following 6 and 12 h of OGD. Data are represented as mean ± SEM. n= 5 cultures. **P < 0.01 in comparison with normal; +++P < 0.001 in comparison
with vehicle-treated group.
Figure 5 IVIg treatment prevents the increased expression of TLR signalling components in vivo following stroke. (A-F) Representative immunoblots
and quantification illustrating increases in the levels of TLR2, TLR4 and TLR8 proteins and both TLR adaptor protein MyD88 and signalling
protein TRAF6 in ipsilateral brain tissues of C57BL/6 J mice following MCAO (1 h) and reperfusion (6 and 24 h). Administration of IVIg (1 g/kg)
significantly prevents the increased expression levels of TLR2, TLR4 and TLR8 as well as MyD88 following 6 and 24 h of cerebral ischemia and
reperfusion (I/R). However, administration of IVIg (1 g/kg) only significantly prevents the increased expression level of TRAF6 in mice subjected
to 6 h of cerebral I/R, not in mice subjected to 24 h of cerebral I/R. Data are represented as mean ± SEM. n = 5 to 6 animals in each group.
##P < 0.01 in comparison with sham; ###P < 0.001 in comparison with sham; *P < 0.05 in comparison with I/R 6; **P < 0.01 in comparison with
I/R 6; ***P < 0.001 in comparison with I/R 6; +P < 0.05 in comparison with I/R 24; +++P < 0.001 in comparison with I/R24; ns, not significant.
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Figure 6 IVIg treatment prevents an increased expression level of the phosphorylated forms of TLR signalling cascade components. IVIg treatment
prevents an increased expression level of the phosphorylated forms of TLR signalling cascade components in vivo following stroke. (A-E) Representative
immunoblots and quantification illustrating increases in the levels of NF-κB-p-p65, p-JNK, p-p38 MAPK and p-c-Jun in ipsilateral brain tissues of C57BL/6 J
mice following MCAO (1 h) and reperfusion (6 and 24 h). Administration of IVIg (1 g/kg) significantly prevents the increased expression levels
of NF-κB-p-p65, p-JNK, p-p38 MAPK and p-c-Jun following stroke. Data are represented as mean ± SEM. n = 5 to 6 animals in each group. #P < 0.05 in
comparison with sham; ##P < 0.01 in comparison with sham; ###P < 0.001 in comparison with sham; *P < 0.05 in comparison with I/R 6; **P < 0.01 in
comparison with I/R 6; ***P < 0.001 in comparison with I/R 6; +P < 0.05 in comparison with I/R 24; ++P < 0.01 in comparison with I/R 24; +++P < 0.001 in
comparison with I/R 24. (F, G) Representative immunoblots and quantification illustrating decrease in the levels of anti-apoptotic Bcl-2 in ipsilateral
brain tissues of C57BL/6 J mice following MCAO (1 h) and reperfusion (6 and 24 h). Administration of IVIg (1 g/kg) significantly prevents a decreased
level of Bcl-2 following stroke. Data are represented as mean ± SEM. n = 5 to 6 animals in each group. ###P < 0.001 in comparison with sham; *P < 0.05
in comparison with I/R 6; +++P < 0.001 in comparison with I/R 24.
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of OGD, however statistical significance was not
reached for the expression level of phosphorylated c-
Jun in neurons treated with 5 mg/ml of IVIg following
6 h of OGD (Figure 3F-J). Consistent with our previ-
ous findings, the immunoblot results showed that IVIg
treatment significantly prevented an increased expres-
sion of cleaved caspase-3 and significantly increased
the expression of Bcl-2 in primary cortical neurons
following 6, 12 and 24 h of GD (Figure 4A-C). Similarly,we have also observed that IVIg treatment signifi-
cantly prevented an increased expression of cleaved
caspase-3 and significantly prevented a decreased ex-
pression of Bcl-2 in OGD 6- and 12-h-treated neurons
(Figure 4D-F). These results not only confirm our pre-
viously published data following GD conditions but
also show for the first time that IVIg can protect neu-
rons following OGD conditions by downregulating
apoptosis and upregulating the anti-apoptotic protein,
Bcl-2.
Figure 7 (See legend on next page.)
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Figure 7 IVIg protects primary neurons against HMGB1-induced cell death by modulating TLRs expression. (A, B) Different concentrations of mouse
recombinant HMGB1 significantly increase oxygen and glucose deprivation (OGD)-induced pro-apoptotic cleaved caspase-3 level. Data are represented
as mean ± SEM. n = 3 cultures. +P < 0.05 in comparison with OGD 4.5-h group; ++P < 0.01 in comparison with OGD 4.5-h group; ns, not significant.
(C-E) Representative immunoblots and quantification illustrating HMGB1 increases the levels of TLR2 and TLR4 in primary cortical neurons
following 4.5 h of OGD. Administration of IVIg (10 mg/ml) significantly prevents HMGB1-induced increased expression level of TLR2 and TLR4.
Data are represented as mean ± SEM. n = 5 cultures. +P < 0.05 in comparison with OGD 4.5-h group; ++P < 0.01 in comparison with OGD 4.5-h
group; *P < 0.05 in comparison with corresponding OGD group; **P < 0.01 in comparison with corresponding OGD group; ***P < 0.001 in
comparison with corresponding OGD group. (F-H) Representative immunoblots and quantification illustrating HMGB1 increases the levels of
MyD88 and TRAF6 in primary cortical neurons following 4.5 h of OGD. Administration of IVIg (10 mg/ml) significantly prevents HMGB1-induced increased
expression level of MyD88 and TRAF6. Data are represented as mean ± SEM. n= 5 cultures. +P< 0.05 in comparison with OGD 4.5-h group; *P < 0.05 in
comparison with corresponding OGD group; ***P< 0.001 in comparison with corresponding OGD group.
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as NF-κB and MAPK activities in vivo following stroke
We previously reported that pre- and post-treatment with
IVIg reduced brain damage and neurological deficits after
cerebral I/R in mice [14]. However, we do not know if the
IVIg-mediated protective effect in vivo is partly achieved
by modulating TLR expression and activation. Therefore,
we next analysed the expression of TLR2, TLR4 and TLR8
in vivo following cerebral I/R injury. Our data showed that
6 and 24 h of cerebral I/R-induced increased expressions
of TL2, TLR4 and TLR8 were significantly prevented by
post-treatment with 1 g/kg body weight of IVIg 3 h after
the onset of reperfusion (Figure 5A-D). We next analysed
the expression levels of TLR adaptor and signalling pro-
teins, MyD88 and TRAF6 following cerebral I/R. Similar
to the in vitro findings, we observed that 3-h post-treatment
with 1 g/kg of IVIg significantly prevented an increased ex-
pression level of MyD88 following 6- and 24-h cerebral I/R
injury (Figure 5A,E). A 1 g/kg of IVIg treatment significantly
prevented an increased expression level of TRAF6 following
6-h cerebral I/R injury, however statistical significance was
not reached following 24-h cerebral I/R injury (Figure 5A,F).
We next analysed the activity of TLR downstream signalling
proteins such as NF-κB and MAPKs in vivo following
cerebral I/R injury. IVIg treatment significantly prevented
an increased expression level of phosphorylated NF-κB
p65 (Figure 6A,B), JNK, p38 MAPK and c-Jun following
6- and 24-h cerebral I/R as compared with control group
(Figure 6A,C-E). Immunoblot analyses showed that IVIg
treatment significantly prevented a decreased level of
Bcl-2 following both 6- and 24-h cerebral I/R as compared
with control group (Figure 6F,G).
IVIg protects neurons against HMGB1-induced cell death
by modulating TLR signalling
High-mobility group box 1 (HMGB1) is a nuclear protein
and has different roles, both intracellularly and extra-
cellularly. Nuclear HMGB1 regulates chromatin structure
and gene transcription whereas extracellular HMGB1 has
shown to bind to receptor for advanced glycation endpro-
ducts (RAGE) and the TLRs [22,23]. In order to investi-
gate the effect of IVIg against HMGB1-mediated TLRsignalling in neurons following OGD, we first determined
the effective concentration of mouse recombinant HMGB1.
Our data showed that HMGB1 above 50 ng/ml was capable
of significantly increasing neuronal cleavage of caspase-3
after 4.5 h of OGD (Figure 7A,B). We next analysed the
effect of IVIg against HMGB1-mediated TLR expression
following OGD. Our data showed that both TLR2 and
TLR4 expression levels were significantly increased follow-
ing HMGB1 treatment when compared to OGD alone
(Figure 7C-E). Furthermore, HMGB1-induced increase
in TLR2 and TLR4 expressions was significantly prevented
by 10 mg/ml of IVIg treatment (Figure 7C-E). Similarly,
the levels of MyD88 and TRAF6 were significantly in-
creased with the addition of HMGB1 to OGD cultures
and IVIg significantly prevented HMGB1-induced in-
crease in MyD88 and TRAF6 following OGD condition
(Figure 7F-H). Next, we analysed HMGB1-mediated TLR
signalling pathways following IVIg treatment. Our data
showed that the levels of NF-κB-p-p65, p-JNK, p38 MAPK
and p-c-Jun expressions were significantly increased
following HMGB1 treatment when compared to OGD
alone (Figure 8A-F). IVIg significantly prevented HMGB1-
induced increases of these proteins following OGD condi-
tion (Figure 8A-F). In addition, our data showed that
OGD-induced cleaved caspase-3 level was significantly
increased in the presence of HMGB1 and this increase was
significantly prevented with IVIg treatment (Figure 8G,H).
Furthermore, the decreased expression level of Bcl-2 was
also prevented by IVIg treatment following HMGB1 treat-
ment (Figure 8G,I). Finally, we analysed the total cellular
HMGB1 and RAGE expression levels. Our data showed
that IVIg treatment resulted in preserving HMGB1 level
(Figure 8J,K). Similar to TLRs, RAGE expression level was
significantly increased following HMGB1 treatments com-
pared to OGD alone (Figure 8J,L) and HMGB1-induced in-
crease in RAGE expression was significantly prevented by
10 mg/ml of IVIg treatment (Figure 8J,L).
Discussion
IVIg therapy has been shown to be effective in the treat-
ment of various inflammatory and autoimmune disorders
[24]. Several mechanisms have been proposed to explain
Figure 8 (See legend on next page.)
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Figure 8 IVIg protects primary neurons against HMGB1-induced cell death by modulating TLR signalling cascades. (A-F) Representative immunoblots
and quantification illustrating HMGB1 increases the levels of NF-κB-p-p65, p-JNK, p-p38 MAPK and p-c-Jun in primary cortical neurons following 4.5 h of
OGD. The increased expression level of p-p65, p-JNK, p-p38 MAPK and p-c-Jun is significantly prevents by administration of IVIg (10 mg/ml) following
HMGB1 treatment. Data are represented as mean ± SEM. n= 5 cultures. +P< 0.05 in comparison with OGD 4.5-h group; ++P < 0.01 in comparison with
OGD 4.5-h group; *P< 0.05 in comparison with corresponding OGD group; **P< 0.01 in comparison with corresponding OGD group; ***P< 0.001 in
comparison with corresponding OGD group. (G-I) Representative immunoblots and quantification illustrating HMGB1 significantly increases the levels of
pro-apoptotic cleaved caspase-3 in primary cortical neurons following 4.5 h of OGD. Administration of IVIg (10 mg/ml) significantly prevents the increased
expression levels of cleaved caspase-3 and significantly prevents the decreased expression levels of Bcl-2 following HMGB1 treatment. Data
are represented as mean ± SEM. n = 5 cultures. +P < 0.05 in comparison with OGD 4.5-h group; *P < 0.05 in comparison with corresponding
OGD group; ***P < 0.001 in comparison with corresponding OGD group; ns, not significant. (J-L) Representative immunoblots and quantification
illustrating the effect of IVIg on the maintenance of intracellular HMGB1 levels and the effect of HMGB1 treatment on the increase in RAGE
levels. Administration of IVIg (10 mg/ml) following HMGB1 treatment was able to significantly prevent HMGB1-induced increased of RAGE
expression. Data are represented as mean ± SEM. n = 5 cultures. +P < 0.05 in comparison with OGD 4.5-h group; *P < 0.05 in comparison with
corresponding OGD group; **P < 0.01 in comparison with corresponding OGD group; ns, not significant.
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tivity of complement system, the expression of adhesion
molecules, the expression and activation of inflammasome
pathways and cytokine production [14,25,26]. IVIg acts
also by dampening pro-inflammatory and apoptotic gene
expressions [15,27]. We and others have previously
demonstrated that IVIg treatment reduced brain dam-
age, neurological deficit and mortality in experimental
rodent models of stroke [14,15,28]. The current study
reveals that a reduction in TLR expression and activa-
tion partly accounts for the protective effect of IVIg
against neuronal cell death following ischemic stroke.
The data indicate that IVIg reduces the expression
levels of TLR2, TLR4 and TLR8 and dampens down-
stream signalling cascades associated with TLRs such
as the NF-κB and MAPKs pathways. Furthermore, our
data show that IVIg is also targeting HMGB1-mediated
TLR signalling in OGD-injured neurons.
Numerous studies have reported pathological roles of
TLRs and RAGE in ischemic stroke-induced brain injury
[7,9,23]. We previously reported that neurons express sev-
eral TLRs, and that the levels of TLR2, TLR4 and TLR8
are increased in neurons in response to ischemic condi-
tions [7,9]. Neurons from both TLR2 knockout and TLR4-
deficient mice were protected against ischemia, and the
amount of brain damage and neurological deficits caused
by a stroke were significantly lesser in mice deficient in
TLR2 or TLR4 compared with control mice [7]. High
concentrations of IVIg prevent neuronal death, but the
neuroprotective mechanism is not well established. Re-
cent studies have indicated that IVIg may attenuate the
expression and activation of TLR9 in B cells from SLE
patients, suggesting a novel additional mechanism of IVIg
[1]. Another recent study showed that IVIg and F(ab)2
fragments of IVIg that lacks the Fc region inhibit TLR4-
mediated activation of dendritic cells [29]. Our data reveals
that treatment with IVIg significantly prevented ischemia-
induced increased neuronal expressions of TLR2, TLR4
and TLR8. In addition, we have also found that ischemia-induced increased expressions of TLR adaptor and signal-
ling proteins such as MyD88 and TRAF6 were prevented
by IVIg treatment. These expression data indicate that IVIg
may exert its beneficial effect by modulating the expression
and activation of neuronal TLR2, TLR4 and TLR8.
It is well established that the activation of NF-κB, JNK
and p38 MAPK pathways are implicated in TLR2, TLR4
and TLR8 signalling [2,30]. Our data show that IVIg treat-
ments significantly attenuated the expression level of the
phosphorylated forms of NF-κB p65, JNK, p38 MAPK and
c-Jun in neurons following ischemic conditions. It is well
known that NF-κB is a regulator of neuronal apoptosis in
cerebral ischemia [31]. Similarly, p38 MAPK, JNK and
c-Jun are known to contribute to neuronal cell death
following ischemic condition [32]. Our data has shown
that IVIg not only prevented ischemia-induced increased
expression levels of TLR2, TLR4 and TLR8 and attenuated
its signalling cascades but also ischemia-induced cleavage
of apoptotic protease caspase-3.
Our data further suggests that IVIg protects neurons
by modulating TLR expression and activation in vitro are
also true for in vivo. We have previously reported that IVIg
treatment reduces brain damage and improves neuro-
logical deficits after cerebral I/R injury [14]. In addition, we
have shown that IVIg reduces ischemic stroke-induced
infiltration of leukocytes and protects against endothe-
lial dysfunction [27]. We also found evidence that the
neuroprotective effects of IVIg are associated with a sig-
nificant reduction in the levels of NLRP inflammasome
proteins as well as precursors of both IL-1β and IL-18 in a
mouse model of focal ischemic stroke [26]. Here, we show
that the increased expression levels of TLR2, TLR4 and
TLR8, adaptor protein MyD88, signalling protein TRAF6,
TLR downstream signalling proteins such as NF-κB and
MAPKs were significantly prevented in IVIg-treated ani-
mals compared to control animals following stroke.
The receptor for advanced glycation endproducts (RAGE)
is a member of the immunoglobulin superfamily that is lo-
cated on the plasma membrane and activated by a variety of
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and HMGB1 [22,23]. Similar to the TLRs, ligand binding to
RAGE leads to the activation of several intracellular inflam-
matory pathways, including NF-κB, JNK and p38 MAPK
[33]. We have recently shown that RAGE-deficient mice
were protected from ischemic stroke and HMGB1 promotes
stroke-induced neuronal cell death by activating signalling
cascades associated with RAGE and TLR activation [23]. Ex-
perimental evidence suggests that HMGB1 is released in
large amounts into the extracellular space immediately
after an ischemic brain insult and subsequently induces
an inflammatory reaction via the activation of the TLRs
and RAGE in affected brain tissues [23]. We have also
demonstrated that recombinant soluble RAGE (sRAGE),
acting as a decoy receptor for HMGB1, significantly re-
duced the infiltration of immune cells and improved the
outcome of injury in mice subjected to I/R as well as pro-
tecting cultured neurons against ischemic cell death [23].
Our current data show that HMGB1 treatment increases
TLR2, TLR4 and RAGE expression levels, and IVIg sig-
nificantly prevented HMGB1-induced increases of these
proteins. Similarly, HMGB1-induced MyD88 and TRAF6
expressions were also significantly prevented with IVIg treat-
ment. Furthermore, IVIg significantly prevented HMGB1-
induced increases of TLR/RAGE signalling cascade proteins
such as NF-κB-p-p65, p-JNK, p-p38 MAPK and p-c-Jun.
Conclusions
Our data establish that IVIg targets expression and acti-
vation of TLR and RAGE pathway components as well
as protecting neurons against HMGB1-mediated neuronal
cell death in ischemic stroke.
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